Seems like a strong breakout for $AMGN

17 sty 2021

Symbol: AMGN

AssetType: Common Stock

Name: Amgen Inc

Description: Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; QIAGEN N.V.; Adaptive Biotechnologies; and Eli Lilly and Company, as well as has a strategic agreement with McKesson Corporation to help improve cancer care in community oncology settings. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Exchange: NASDAQ

Currency: USD

Country: USA

Sector: Healthcare

Industry: Drug Manufacturers-General

Address: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799

FullTimeEmployees: 23400

FiscalYearEnd: December

LatestQuarter: 2020-09-30

MarketCapitalization: 142916681728

EBITDA: 12647000064

PERatio: 19.7992

PEGRatio: 1.5407

BookValue: 18.781

DividendPerShare: 7.04

DividendYield: 0.0287

EPS: 12.399

RevenuePerShareTTM: 42.405

ProfitMargin: 0.2942

OperatingMarginTTM: 0.3757

ReturnOnAssetsTTM: 0.0945

ReturnOnEquityTTM: 0.6718

RevenueTTM: 24987000832

GrossProfitTTM: 19006000000

DilutedEPSTTM: 12.399

QuarterlyEarningsGrowthYOY: 0.049

QuarterlyRevenueGrowthYOY: 0.12

AnalystTargetPrice: 255.28

TrailingPE: 19.7992

ForwardPE: 13.7741

PriceToSalesRatioTTM: 5.5562

PriceToBookRatio: 12.4317

EVToRevenue: 6.4341

EVToEBITDA: 12.4492

Beta: 0.7616

52WeekHigh: 261.431

52WeekLow: 173.5108

50DayMovingAverage: 229.69

200DayMovingAverage: 238.9139

SharesOutstanding: 582169024

SharesFloat: 581126530

SharesShort: 6958047

SharesShortPriorMonth: 6912555

ShortRatio: 2.82

ShortPercentOutstanding: 0.01

ShortPercentFloat: 0.012

PercentInsiders: 0.188

PercentInstitutions: 77.988

ForwardAnnualDividendRate: 7.04

ForwardAnnualDividendYield: 0.0287

PayoutRatio: 0.3993

DividendDate: 2021-03-08

ExDividendDate: 2021-02-11

LastSplitFactor: 2:1

LastSplitDate: 1999-11-22